Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Assertio Therapeutics (ASRT) stocks
Learn how to easily invest in Assertio Therapeutics stocks.
Assertio Therapeutics is a drug manufacturers-specialty & generic business based in the US. Assertio Therapeutics stocks (ASRT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.62 – a decrease of 2.31% over the previous week. Assertio Therapeutics employs 30 staff and has a trailing 12-month revenue of around $162.2 million.
How to buy Assertio Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ASRT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
CIBC Investor's Edge
- Easy to use platform
- Low fees
- Student and young investor discounts
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
National Bank Direct Brokerage
- Commission-free trading
- Several account types available
- Access to array of research tools
What's in this guide?
- Can I buy shares in Assertio Therapeutics?
- Has coronavirus impacted Assertio Therapeutics shares?
- Assertio Therapeutics shares summary
- Compare share dealing platforms
- Is Assertio Therapeutics stock a buy or sell?
- Assertio Therapeutics performance over time
- Are Assertio Therapeutics shares over-valued?
- Assertio Therapeutics's financials
- How volatile are Assertio Therapeutics shares?
- Does Assertio Therapeutics pay a dividend?
- Have Assertio Therapeutics shares ever split?
- Other common questions
Assertio Therapeutics stock price (NASDAQ:ASRT)Use our graph to track the performance of ASRT stocks over time.
Assertio Therapeutics shares at a glance
|Latest market close||$6.35|
|52-week range||$2.07 - $8.01|
|50-day moving average||$6.30|
|200-day moving average||$4.26|
|Wall St. target price||$9.75|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.77|
Buy Assertio Therapeutics stocks from these online trading platformsCompare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Assertio Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Assertio Therapeutics price performance over time
Historical closes compared with the close of $6.35 from 2023-06-02
|1 week (2023-05-26)||-2.31%|
|1 month (2023-05-05)||3.25%|
|3 months (2023-03-03)||2.25%|
|6 months (2022-12-05)||93.01%|
|1 year (2022-06-03)||99.06%|
|2 years (2021-06-04)||252.78%|
|3 years (2020-06-05)||537.93%|
|5 years (2018-06-05)||6.35|
Is Assertio Therapeutics stock undervalued or overvalued?
Valuing Assertio Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Assertio Therapeutics's P/E ratio
Assertio Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Assertio Therapeutics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Assertio Therapeutics's PEG ratio
Assertio Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6155. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Assertio Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Assertio Therapeutics's EBITDA
Assertio Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $88.5 million.
The EBITDA is a measure of a Assertio Therapeutics's overall financial performance and is widely used to measure a its profitability.
Assertio Therapeutics financials
|Revenue TTM||$162.2 million|
|Operating margin TTM||35.37%|
|Gross profit TTM||$138.3 million|
|Return on assets TTM||9.52%|
|Return on equity TTM||53.56%|
|Market capitalisation||$353.5 million|
TTM: trailing 12 months
Assertio Therapeutics share dividends
We're not expecting Assertio Therapeutics to pay a dividend over the next 12 months.
Have Assertio Therapeutics's shares ever split?
Assertio Therapeutics's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio Therapeutics shares which in turn could have impacted Assertio Therapeutics's share price.
Assertio Therapeutics share price volatility
Over the last 12 months, Assertio Therapeutics's shares have ranged in value from as little as $2.07 up to $8.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio Therapeutics's is 1.3962. This would suggest that Assertio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Assertio Therapeutics overview
Assertio Holdings, Inc. , a commercial pharmaceutical company, provides medicines in the areas of neurology, rheumatology, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.
Stocks similar to Assertio Therapeutics
Assertio Therapeutics in the news
Does Assertio Holdings (NASDAQ:ASRT) Deserve A Spot On Your Watchlist?
Assertio Holdings First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Q1 2023 Assertio Holdings Inc Earnings Call
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.Read more…
Best stock app for beginners for 2023
The best stock trading app for beginners is easy to use and offers free trades.Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.Read more…
More guides on Finder
Bad credit loans in Edmonton, Alberta
From personal and payday loans to lines of credit, compare loans for bad credit in Edmonton.
How to buy Sui (SUI) in Canada
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
How to buy Pepe (PEPE) in Canada
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
How to buy Arbitrum (ARB) in Canada
This guide provides step-by-step instructions on how to buy Arbitrum, lists some exchanges where you can get it and provides daily price data on (ARB).
How to buy SSV Network (SSV) in Canada
This guide provides step-by-step instructions on how to buy SSV Network, lists some exchanges where you can get it and provides daily price data on (SSV).
How to buy USDD (USDD) in Canada
This guide provides step-by-step instructions on how to buy USDD, lists some exchanges where you can get it and provides daily price data on (USDD).
How to buy Blur (BLUR) in Canada
This guide provides step-by-step instructions on how to buy Blur, lists some exchanges where you can get it and provides daily price data on (BLUR).
How to buy FLOKI Inu (FLOKI) in Canada
This guide provides step-by-step instructions on how to buy FLOKI Inu, lists some exchanges where you can get it and provides daily price data on (FLOKI).
How to buy Aptos (APT) in Canada
This guide provides step-by-step instructions on how to buy Aptos, lists some exchanges where you can get it and provides daily price data on (APT).
How to buy EthereumPoW (ETHW) in Canada
This guide provides step-by-step instructions on how to buy EthereumPoW, lists some exchanges where you can get it and provides daily price data on (ETHW).